Abstract
INTRODUCTION
The establishment of Pseudomonas aeruginosa chronic respiratory infection is mediated by a complex adaptive process that includes physiological changes, mainly represented by the transition from planktonic to the biofilm mode of growth (3) , and the selection of an important number of adaptive mutations required for long-term persistence (42). The biofilm mode of growth is one of the most important factors in the persistence of chronic lung infections due to its increased resistance to the host defense mechanisms, including the mechanical clearance and that mediated by complement, antibodies, or phagocytes, and its inherent resistance to the antibiotics (14).
A common feature of P. aeruginosa chronic lung infections, including those occurring in patients suffering from cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), is the very high prevalence (30 to 60% of patients) of hypermutable (or mutator) strains deficient in the DNA mismatch repair system, in contrast to what is observed in acute infections (<1%) (2, 8, 23, 31, 32) . The presence of hypermutable strains has been found to be linked to the high antibioticresistance rates of P. aeruginosa strains isolated from patients with chronic lung infections (23, 32). It has been also shown by in vitro and in vivo experiments that hypermutation dramatically favors resistance development during antibiotic exposure (24, 33, 36) . A recent work has also shown that hypermutation favors the establishment of chronic colonization in the CF mice model, likely by facilitating the acquisition of adaptive mutations (27) . One of the most frequent and relevant adaptive mutations in P. aeruginosa strains causing chronic lung infections is the inactivation of mucA that leads to alginate hyperproduction (7) . Mucoid variants are found in 80 to 90% of chronically infected patients and are associated with a poorer pulmonary outcome. Alginate hyperproduction is
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on September 12, 2017 by guest http://aac.asm.org/ Downloaded from also known to reduce bacterial clearance (35), to inhibit phagocytosis (34), complement activation (37), antibiotic penetration (9) and neutralization of oxygen radicals (40).
Therefore, once chronic infection by P. aeruginosa is established, its eradication using conventional antibiotic treatments is extremely difficult, if not impossible.
In the last years, azithromycin (AZM), a macrolide antibiotic, has shown promising results in the treatment of chronic infections by P. aeruginosa. Although macrolides are not active against P. aeruginosa in standard in vitro susceptibility tests, these antibiotics show bactericidal activity on stationary phase (16). Furthermore, AZM is known to inhibit biofilm growth and the production of alginate and other virulence factors, likely due to its interaction with the quorum sensing system (QS) (15, 44, 45) . In fact, AZM is widely used currently as maintenance therapy in P. aeruginosa chronic respiratory infections, since several studies have demonstrated its clinical benefit (4, 46) . Nevertheless, it has not been yet evaluated whether AZM treatment determines a pressure for the selection of resistant mutants, neither if this potential effect might be favored by the hypermutable and/or mucoid phenotypes. Therefore, in this work, we evaluated the individual and combined effect of hypermutation and alginate hyperproduction on the bactericidal activity and resistance development to AZM in P. aeruginosa biofilms in vitro. 
on
MATERIALS AND METHODS
Bacterial strains and plasmids. The strains and plasmids used in this study are listed in Table 1 . PAO1 single or double knockout mutants in mucA, mutS, nfxB and mexD were constructed following the procedure previously described by Quénée et al.
(38) for gene deletion and antibiotic marker recycling in P. aeruginosa. Upstream and downstream PCR products (Table 2) were digested with either BamHI or EcoRI and HindIII and cloned by two-way ligation into pEX100Tlink with the HindIII site deleted and opened by EcoRI and BamHI. Resulting plasmids were transformed into E. coli XL1-Blue, and transformants were selected in 50 µg/ml ampicillin MacConkey agar plates. The cloned PCR products were sequenced to verify the absence of mutations generated during PCR amplification. The lox-flanked gentamicin resistance cassette (aacC1) obtained by HindIII restriction of plasmid pUCGmlox was cloned into the single site for this enzyme formed by ligation of the two flanking fragments, and resulting plasmids were transformed into E. coli XL1-Blue. Transformants were selected in 30 µg/ml ampicillin-5 µg/ml gentamicin Luria Bertani (LB) agar plates. These plasmids were then transformed into E. coli helper strain S17-1. Knockout mutants were generated by conjugation followed by selection of double recombinants using 5% sucrose-30 µg/ml gentamicin LB agar plates. Double recombinants were checked first screening for carbenicillin (200 µg/ml) susceptibility and afterwards by PCR amplification and sequencing. For the recycling of the gentamicin resistance cassettes, plasmid pCM157 was electroporated into the different mutants as previously described (41). Transformants were selected in 250 µg/ml tetracycline LB agar plates. One transformant for each mutant was grown overnight in 250 µg/ml tetracycline LB broth in order to allow the expression of the cre recombinase.
Plasmid pCM157 was then cured from the strains by successive passages on LB broth. Selected colonies were then screened for tetracycline (250 µg/ml) and gentamicin (30
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on September 12, 2017 by guest http://aac.asm.org/ Downloaded from µg/ml) susceptibility and checked by PCR amplification and DNA sequencing to ascertain that the corresponding genes were properly disrupted. The double mutants were then constructed from the single mutants following the same procedure. The appropriate phenotypes of the constructed mutants were ascertained by the mucoid phenotype (mucA), the approx. 2 log increase in the rifampicin resistance mutation rates (mutS) (33) or the expression of mexD (nfxB and mexD).
Antimicrobial susceptibility studies on planktonically growing cells.
Conventional Minimal Inhibitory Concentrations (MICs) of ceftazidime, cefepime, aztreonam, imipenem, ciprofloxacin, tobramycin and colistin were determined in Müller-Hinton agar (MHA) plates using E-test strips (AB Biodisk, Sweden) following the manufacturers recommendations. AZM MICs were determined by microdilution (range of AZM concentrations from 0.5 to 1024 µg/ml) in Müller-Hinton broth (MHB) using a final bacterial inoculum of 5x10 5 log-phase CFU/ml. The effect of long-term exposure of planktonically growing cells to subinhibitory concentrations of azithromycin was also investigated. For this purpose, strains PAO1 or PAOMS were inoculated into six 10 ml MHB tubes containing 4 µg/ml of AZM. Cultures were incubated during 7 days at 37ºC and 180 rpm with daily dilution (1/100) into a fresh tube. After the 7 days, serial dilutions of the cultures were seeded in MHA plates. Two colonies from each of the six independent replicate experiments per strain were stored frozen at -80ºC for further studies.
Antimicrobial susceptibility studies on biofilms. were also conducted afterwards using the nfxB and mexD knockout of PAO1 or PAOMS.
The activity of ciprofloxacin on biofilms formed by these mutants was also assessed, following for this purpose the above described procedure (24 h incubation experiments) using concentrations of 0.125, 0.25, 0.5, 1, and 2 µg/ml. 
Investigation

RESULTS
Effect of mutS and/or mucA inactivation on AZM activity against planktonic cells and biofilms.
As expected, P. aeruginosa planktonically grown cells were found to be highly resistant to AZM. Furthermore, the MIC in the microdilution susceptibility assay was 128 µg/ml for the four strains (PAO1, PAOMA, PAOMS, and PAOMSA), showing that neither mucA or mutS inactivation had major effects on AZM susceptibility. Figure 1 ). In the 24h (t=1d) biofilms assays, AZM exhibited a concentration-dependent bactericidal activity, and concentrations as low as 0.5 µg/ml determined a significant reduction in the bacterial load ( Figure 1 ). For PAO1, the reduction in the bacterial load at t=1d ranged from 2 log with AZM 0.5 µg/ml to 4 log with AZM 256 µg/ml ( Figure 1 ). Results were similar for PAOMS, but AZM activity at t=1d tended to be lower for the mucA strains, particularly for the mucA-mutS double mutant (PAOMSA); the reduction in the bacterial load for PAOMSA ranged from approximately 2-fold with AZM 0.5 µg/ml, to 2 log with AZM 256 µg/ml ( Figure 1 ). The reduction in the bacterial load observed at t=1d for all strains and AZM concentrations was further increased at t=2d in all cases. Again, the overall reduction in the bacterial loads was lowest for PAOMSA. After extended AZM incubation (t=4d and t=7d), the bacterial load was stabilized (similar from t=2d to t=7d) for the lower concentrations (0.5 and 1 µg/ml) in the four strains ( Figure 1 ). Nevertheless, the reduction in the bacterial load continued up to t=7d for strains PAO1 and PAOMA for concentrations ≥ 4 µg/ml. On the other hand, extended AZM incubation (t=4d and t=7d), for strain PAOMS, and especially PAOMSA, Mutants showing resistance to AZM activity on biofilms are selected during treatment.
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Above results suggested that AZM resistant populations were being selected in biofilms of the mutS strains during exposure to AZM 4 µg/ml. Therefore, twelve stored lineages per strain (PAOMS and PAOMSA) from the t=7d-AZM 4 µg/ml biofilm experiments were investigated. To determine whether the high increase in the numbers of viable cells was due to the selection of a stable AZM resistance mechanism, the lineages were retested in the biofilm treatment assay (t=1d) with 4 µg/ml AZM. As shown in To explore whether cross resistance to conventional antipseudomonal agents was developed during AZM exposure, MICs of ciprofloxacin, ceftazidime, cefepime, aztreonam, tobramycin and colistin were initially determined in the 12 above described lineages of PAOMS and PAOMSA. Indeed, the antibiotic susceptibility profile showed
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MICs to ciprofloxacin and cefepime. Considering these results, we decided to evaluate whether cross resistance was also being selected in the non-hypermutable strains (PAO1 and PAOMA) and at the other AZM concentrations. Thus, we determined the MICs of ciprofloxacin in the 12 stored lineages of the four strains, recovered from t=7d biofilms treated with AZM 0, 0.5, 1 or 4 µg/ml. The ciprofloxacin resistance screening was considered positive when the documented MIC for this antibiotic was more than one twofold dilution higher than for the wild-type strains (MIC > 0.25 µg/ml). As shown in Table   3 , for strains PAO1 and PAOMA a low number (1-2) of the tested lineages met this criterion, indicating, nevertheless, that resistant mutants were indeed selected in nonhypermutable strains even at concentrations as low as 0.5 µg/ml. In strains PAOMS and PAOMSA, this proportion was much larger, and most of the lineages recovered from the t=7d AZM-treated biofilms showed ciprofloxacin resistance, even those treated with 0.5 µg/ml (Table 3) . In contrast, all the lineages recovered from non treated biofilms of the four strains showed wild-type ciprofloxacin MICs.
To explore the susceptibility profile of the detected ciprofloxacin resistant lineages, the MICs of ceftazidime, cefepime, aztreonam, imipenem, tobramycin and colistin were determined. As shown in Table 4 , all the mutants showed increased resistance to ciprofloxacin (MICs ranging from 0.5 to 4 µg/ml) and cefepime (MICs ranging from 6 to basal expression. In order to investigate the mechanisms leading to MexCD-OprJ hyperexpression, nfxB was sequenced in these lineages, revealing in all cases the presence of mutations in this regulatory gene (Table 4) . Eighteen different types of mutations in nfxB were detected in the studied collection. The most frequently found were missense mutations, detected in 19 of the 25 studied lineages. Frequently (10 of 19), the missense mutations involved a Leu to Pro change, occurring in several different residues of NfxB ( Should be noted at this stage, however, that a 100% correlation between development of AZM resistance (data on Figure 1 ) and the acquisition of nfxB mutations (data on Table 4 ) was not observed. As describe above and shown in Figure 1 , most of the lineages tested (21 of the 24) from AZM-4µg/ml 7 days biofilms showed AZM resistance, and all the 16 nfxB mutants (Table 4) were among the 21 resistant lineages. Nevertheless, interestingly, still 5 of the 21 resistant lineages had no nfxB mutations (neither NfxB phenotype). These results indicate that, despite nfxB mutants are clearly positively selected during AZM treatment, there are yet unidentified mechanisms that can also drive AZM resistance development in biofilms.
Characterization of nfxB and mexD knockout mutants.
In order to further understand the role of the efflux pump MexCD-OprJ in AZM resistance, we constructed and characterized the nfxB and mexD knockout mutants, leading to the constitutive upregulation and the inactivation of the efflux pump, respectively. As could be expected, the inactivation of nfxB dramatically increased mexD expression and (Table 4) . On the other hand, as also could be expected, the inactivation of mexD did not significantly modify the MICs of quinolones, β-lactams or aminoglycosids (Table 4) . Moreover, the inactivation of nfxB increased further (to 512 µg/ml) the already high AZM MICs of wild-type strains (128 µg/ml), whereas mexD inactivation resulted in no effect. Consistently with the results of this work, the nfxB knockout mutant of PAO1 showed significantly enhanced AZM resistance in biofilm growth (1-2 Log increased survival rates) at all concentrations ranging from 0.5 to 4 µg/ml ( Figure 3A ). As shown in Figure 3B , the effect of nfxB inactivation on resistance was even much more pronounced when ciprofloxacin was tested. On the other hand, the inactivation of mexD did not increase susceptibility neither to AZM or ciprofloxacin (Figure 3) , showing that MeCD-OprJ does not play a significant role unless it is overexpressed through nfxB mutation. There are not too much data concerning antibiotic susceptibility assays in biofilm.
A work by Moskowittz et al. (28) showed that the biofilm inhibitory concentrations (BIC)
were much higher than the corresponding conventionally determined MICs for all the antibiotics tested (β-lactams, tetracyclin, quinolones and aminoglycosides) except for AZM, that appeared much more active against biofilm-grown P. aeruginosa. The results of this work show that AZM exhibits bactericidal activity on P.
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aeruginosa biofilms in vitro demonstrated by the marked reduction in the numbers of viable cells, even at concentrations as low as 0.5 µg/ml. Overall, alginate hyperproduction did not significantly modify AZM activity, although the reduction in the bacterial loads tended to be lower for the mucA strains in t=1d experiments, suggesting that alginate may protect P. aeruginosa biofilms from AZM to some extent. Nevertheless, the most significant differences on the overtime dynamics of bacterial populations in AZM-treated biofilms were observed between non-hypermutable and hypermutable strains. Indeed, a marked selection of AZM resistant mutants was demonstrated for PAOMS, and especially for PAOMSA. Remarkably, in most cases, AZM resistance was found to be mediated by the selection of mutants that hyperproduce the multi-drug efflux pump MexCD-OprJ.
Given the high prevalence of P. aeruginosa hypermutable strains in chronic respiratory infections, the notable amplification of AZM resistant mutants that are also resistant to ciprofloxacin and cefepime, alerts about the impact of AZM maintenance treatment in these patients. Furthermore, although to a much lower extent, MexCD-OprJ hyperproducing mutants were also selected in the non-hypermutable strains. It has also been shown previously that hyperexpression of MexCD-OprJ is a frequent fluoroquinolone resistance mechanism among P. aeruginosa strains isolated from CF patients, while it is uncommon in other settings (10, 18, 19). A positive in vivo selection of In all cases, MexCD-OprJ hyperexpression was found to be driven by mutations in its negative regulator nfxB. We detected up to eighteen types of different mutations in this gene in the 25 mutants studied. As observed for the few P. aeruginosa clinical strains that have been investigated so far (10, 11, 18, 19), the most frequently found were missense mutations, detected in 19 of the 25 studied lineages. Frequently (10 of 19), the missense mutations involved a Leu to Pro change, occurring in several different residues of NfxB.
On the other hand, directly inactivating mutations (nonsense mutations, frameshifts, In summary, we show that although AZM exhibits bactericidal activity against P.
aeruginosa biofilms, resistant mutants are readily selected, particularly for hypermutable strains. The main AZM resistance mechanism is found to be the hyperexpression of MexCD-OprJ due to mutations in its negative regulator gene, nfxB. This mechanism confers resistance to relevant unrelated antipseudomonal agents such as ciprofloxacin or cefepime, but may confer hypersusceptiblity to others such as aminoglycosides. Therefore, (43) . The ciprofloxacin resistance screening was considered positive when the documented MIC for this antibiotic was more than one two-fold dilution higher than for the wild-type strains (MIC > 0.25 µg/ml). c Concentrations (µg/ml) of azithromycin (AZM) used in the 7-days biofilms experiments. 
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